Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Received IND clearance and initiated first-in-human Phase 1 clinical trial for lead asset, ADI-001, an
Received IND clearance and initiated first-in-human Phase 1 clinical trial for lead asset, ADI-001, an
We expect to report top line data from our Phase 2 cystic fibrosis clinical trials
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing
Hemp/Hashish Franchise Highlights and Recent Essential Gatherings Given that reporting 3rd quarter earnings, 22nd Century
Key Business and Financial Highlights 22nd Century has a tremendous global commercial opportunity in the
News Highlights Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second
Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second quarter 2021
PCDH19 related epilepsy (PCDH19-RE) Phase 2 Violet Study Proof-of-Concept Trial (n=21) shows a median 61.5{f13b67734a7459ff15bce07f17c500e58f5449212eae0f7769c5b6fbcf4cc0c4}
Sale of Manufacturing Operations to Catalent with net proceeds of ~$74 million Annual operating expenses
The MarketWatch News Department was not involved in the creation of this content. ENGLEWOOD, Colo.,
The MarketWatch News Department was not involved in the creation of this content. NEVE ILAN,
Push release material from World Newswire. The AP information team was not included in its
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb 23, 2021– Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing
2020 Net Revenues of $83.1 Million Increased 19{f13b67734a7459ff15bce07f17c500e58f5449212eae0f7769c5b6fbcf4cc0c4} over 2019 Fourth Quarter Net Revenues of
Push launch content from Globe Newswire. The AP news personnel was not included in its
NEW HAVEN, Conn., March 1, 2021 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven” or the
Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company Lucid Diagnostics
IRVINE, Calif.–(BUSINESS WIRE)–Feb 22, 2021– Sabra Health Care REIT, Inc. (“Sabra,” the “Company” or “we”)